Advertisements

Pivotal Therapeutics Inc. (PVO:CNX) Stock Quote

Detailed Quote for Pivotal Therapeutics Inc. (PVO:CNX)
$ 0.065 0.00 (0.00%) Volume: 250 3:20 PM EDT Jul 6, 2015
Today 5d 1m 3m 1y more
Last Price
0.065
Change $
Change %
Tick
N/A
Bid
0.05
Bid Size
70,000
Ask
0.065
Ask Size
30,000
Open
N/A
High
N/A
Low
N/A
Prev Close
0.065
Last Trade
07/06/15
Volume
250
52 Wk Hi
0.18
52 Wk Low
0.02
Market Cap
6.18m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
95,013,710
EPS (TTM)
-0.05
PE Ratio
N/A
Exchange
CSE
News and Media for Pivotal Therapeutics Inc. (PVO:CNX)
Sector News | Topic News
News for Pivotal Therapeutics Inc. (PVO:CNX)
Mon, Jun 29, 2015
8:43 PM Pivotal Therapeutics Announces Proposed Private Placement - TheNewsWire
Thu, Jun 18, 2015
5:53 PM Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes - Canada Newswire
Thu, Jun 04, 2015
2:25 PM First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100 - PR Newswire
2:25 PM First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100 - Canada Newswire
Mon, Jun 01, 2015
9:19 PM Pivotal Therapeutics Announces First Quarter Financial Results - Canada Newswire
9:19 PM Pivotal Therapeutics Announces First Quarter Financial Results - PR Newswire
Mon, May 11, 2015
3:17 PM Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel - PR Newswire
3:17 PM Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel - Canada Newswire
Thu, Apr 30, 2015
9:20 PM Pivotal Therapeutics Announces 2014 Financial Results - Canada Newswire
9:20 PM Pivotal Therapeutics Announces 2014 Financial Results - PR Newswire
Mon, Apr 27, 2015
12:48 PM Pivotal receives Health Canada approval to expand the indication of OMAZEN\u00AE to include products with claims to maintain and support cardiovascular health and normal triglyceride levels - Canada Newswire
12:48 PM Pivotal receives Health Canada approval to expand the indication of OMAZEN\u00AE to include products with claims to maintain and support cardiovascular health and normal triglyceride levels - PR Newswire
Wed, Apr 15, 2015
9:10 AM Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial(TM) line of products in Korea - Canada Newswire
9:10 AM Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial(TM) line of products in Korea - PR Newswire
Tue, Apr 07, 2015
11:00 AM Pivotal Therapeutics and French University Hospital of Strasbourg Announce POMEGA Trial Chief Investigator Dr. Yannick Georg Laureate of EUR 30,000 French Interregional Clinical Research and Innovation Award For Investigating the Therapeutic Value of Its Novel VASCAZEN\u00AE Formulation in France - PR Newswire
11:00 AM Pivotal Therapeutics and French University Hospital of Strasbourg Announce POMEGA Trial Chief Investigator Dr. Yannick Georg Laureate of EUR 30,000 French Interregional Clinical Research and Innovation Award For Investigating the Therapeutic Value of Its Novel VASCAZEN\u00AE Formulation in France - Canada Newswire
Wed, Apr 01, 2015
4:16 PM Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN\u00AE and an Omega-3 Fatty Acid Diagnostic Assay - PR Newswire
3:44 PM Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN\u00AE and an Omega-3 Fatty Acid Diagnostic Assay - Canada Newswire
3:44 PM Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN\u00AE and an Omega-3 Fatty Acid Diagnostic Assay - PR Newswire
Thu, Mar 26, 2015
5:13 PM Pivotal Therapeutics announces payment of interest on outstanding convertible notes - Canada Newswire
More News for PVO:CNX >>

Tags for Pivotal Therapeutics Inc.

Research stocks or mutual funds related to Pivotal Therapeutics Inc. by keywords or tags. Find companies that have a similar focus to PVO:CNX. The keywords below have been associated to PVO:CNX by either user submission or electronic means.